Capricor Therapeutics Faces a Harrowing 65% Drop Amid FDA Concerns: A Cautionary Tale for Investors
Capricor Therapeutics' stock plummets 65% after FDA documents raise concerns about deramiocel, highlighting biotech investment risks.
Altimmune's Clinical Triumph: What the Phase 2 RECLAIM Data Means for Investors
Altimmune's shares surged 18% following promising Phase 2 data for pemvidutide, signaling a bright future for the company.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Curium's Potential $7 Billion Acquisition of Lantheus Holdings: What Investors Need to Know
Curium's potential acquisition of Lantheus Holdings could reshape the radiopharmaceutical landscape, but what does this …
Outlook Therapeutics (OTLK) Rises Dramatically Following FDA Approval of Lytenava
OTLK's stock jumps after FDA approval of Lytenava, with analysts projecting nearly 300% upside ahead of its launch.
Capricor Therapeutics (CAPR) Faces Devastating Losses Following FDA Concerns
Capricor Therapeutics suffers a staggering 67% drop as FDA concerns about Deramiocel loom large, dividing analysts on ap…
SNDL Inc. Expands U.S. Footprint with Acquisition of Parallel Assets: What It Means for Investors
SNDL's acquisition of Parallel positions it strategically in the U.S. cannabis market, signaling potential growth and in…
Outlook Therapeutics (OTLK) Stock Soars After FDA Approval: What Investors Should Know
Outlook Therapeutics shares rise after FDA approval of LYTENAVA, with a significant analyst upgrade and potential for ma…
Capricor Therapeutics (CAPR): A Cautionary Tale for Biotech Investors Following 67% Drop
Capricor Therapeutics plummets 67% amid FDA concerns, highlighting the high-stakes nature of biotech investments.
Expand Energy's Acquisition of Twin Eagle: A Game Changer for Natural Gas Market
Expand Energy's acquisition of Twin Eagle could reshape North America's natural gas landscape amidst rising geopolitical…
Capricor Therapeutics Faces Critical FDA Review: What’s Next for CAPR Investors?
Capricor Therapeutics navigates a critical FDA review, impacting stock dynamics and future growth potential.
OTLK Stock Soars After FDA Approval: What Investors Need to Know
Outlook Therapeutics' FDA approval for its wet AMD drug could signal a significant opportunity for investors in OTLK sto…